Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program

Pathology

Volumn 42, Issue 7, 2010, Pages 637-642

  Hung, Tawny ^a   Wolber, Robert ^b   Garratt, John ^a   Kalloger, Steven ^a   Gilks, C Blake ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b LIONS GATE HOSPITAL   (Canada)

Author keywords

Breast biomarkers; ER; HER2; PR; Proficiency testing; Quality assurance

Indexed keywords

EID: 78649281123     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313025.2010.520306     Document Type: Article

References (17)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2007. Toronto: Canadian Cancer Society/National Cancer Institute of Canada, 2007.
2. Terry J, Torlakovic E, Garratt J, et al. Implementation of a Canadian external quality assurance program for breast cancer biomarkers. Appl Immunohistochem Mol Morphol 2009;17:375-82.
3. Rhodes A, Jasani B, Balaton AJ, Miller KD. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 2000;53:292-301.
4. Regitnig P, Reiner A, Dinges HP, et al. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 2002;441:328-34.
5. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-30.
6. Francis GD, Dimech M, Giles L, Hopkins A. Frequency and reliability of oestrogen receptor, progesteron receptor, and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol 2007;60:1277-83.
7. Torlakovic EE, Riddell R, Hewlett B, et al. Best practice recommendations for standardization of immunohistochemistry tests. Can J Pathol 2009;1:14-25.
8. Gown AM. Current Issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008;21: S8-15.
9. Oyama T, Ishikawa Y, Hayashi M, Arihiro K, Horiguchi J. The effects of fixation, processing, and evaluation on Immunohistochemical detection of hormone receptors in breast cancer. Breast Cancer 2007;14:182-8.
10. Gown AM. Tweaking and nudging toward improved IHC quality. Appl Immunohistochem Mol Morphol 2009;17:363-5.
11. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004;17:1545-54.
12. Vyberg M. NordiQC: Nordic Immunohistochemical Quality Control. Denmark: NordiQC, 2009. http://www.nordiqc.org/Participation.htm, accessed 25 November 2009.
13. Royal College of Pathologists of Australasia Quality Assurance Program (RCPA-QAP). RCPA Anatomical Pathology QAP. Sydney: RCPA-QAP, 2009. http://www.rcpaqapa.netcore.com.au/cgi-bin/site/wrapper.pl?c1=Program, accessed 25 November 2009.
14. UK NEQAS. UK NEQAS for Immunocytochemistry and in-situ Hybridisation. London: UK NEQAS, 2009. http://www.ukneqasicc. ucl.ac.uk/, accessed 25 November 2009.
15. Murphy, Hilda. College of American Pathologists: Proficiency Testing. Northfield: CAP, 2009. http://www.cap.org/apps/cap. portal?-nfpb=true&- pageLabel=contact-cap-page&client-ccap-1-actionOverride=/portlets/ ClientCTCAP/viewCase&client-ccap-1confirmationNbr=2009 1125050930, accessed 30 November 2009.
16. Parker RP, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002;117:723-8.
17. Sauter G, Lee J, Bartlett JM, Slamon DJ, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009;8:1323-33.